Literature DB >> 30851065

Functional characterization of CHEK2 variants in a Saccharomyces cerevisiae system.

Angeliki Delimitsou1,2, Florentia Fostira1, Despoina Kalfakakou1, Paraskevi Apostolou1, Irene Konstantopoulou1, Christos Kroupis3, Athanasios G Papavassiliou4, Zdenek Kleibl5, Efstratios Stratikos6, Gerassimos E Voutsinas2, Drakoulis Yannoukakos1.   

Abstract

Genetic testing for cancer predisposition leads to the identification of a number of variants with uncertain significance. To some extent, variants of BRCA1/2 have been classified, in contrast to variants of other genes. CHEK2 is a typical example, in which a large number of variants of unknown clinical significance were identified and still remained unclassified. Herein, the CHEK2 variant assessment was performed through an in vivo, yeast-based, functional assay. In total, 120 germline CHEK2 missense variants, distributed along the protein sequence, and two large in-frame deletions were tested, originating from genetic test results in breast cancer families, or selected from the ClinVar database. Of these, 32 missense and two in-frame deletions behaved as non-functional, 73 as functional, and 15 as semi-functional, after comparing growth rates of each strain with positive and negative controls. The majority of non-functional variants were localized in the CHK2 kinase and forkhead-associated domains. In vivo results from the non-functional variants were in agreement with in silico predictions, and, where available, with strong breast cancer family history, to a great extent. The results of the largest, to date, yeast-based assay, evaluating CHEK2 variants, can complement and assist in the classification of rare CHEK2 variants with unclear clinical significance.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  CHEK2 variants; breast cancer; functional assay; yeast

Mesh:

Substances:

Year:  2019        PMID: 30851065     DOI: 10.1002/humu.23728

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  10 in total

1.  Identification and prioritization of myeloid malignancy germline variants in a large cohort of adult patients with AML.

Authors:  Fei Yang; Nicola Long; Tauangtham Anekpuritanang; Daniel Bottomly; Jonathan C Savage; Tiffany Lee; Jose Solis-Ruiz; Uma Borate; Beth Wilmot; Cristina Tognon; Allison M Bock; Daniel A Pollyea; Saikripa Radhakrishnan; Srinidhi Radhakrishnan; Prapti Patel; Robert H Collins; Srinivas Tantravahi; Michael W Deininger; Guang Fan; Brian Druker; Ujwal Shinde; Jeffrey W Tyner; Richard D Press; Shannon McWeeney; Anupriya Agarwal
Journal:  Blood       Date:  2022-02-24       Impact factor: 25.476

2.  Prevalence of germline variants in consensus moderate-to-high-risk predisposition genes to hereditary breast and ovarian cancer in BRCA1/2-negative Brazilian patients.

Authors:  Renan Gomes; Pricila da Silva Spinola; Ayslan Castro Brant; Bruna Palma Matta; Caroline Macedo Nascimento; Silvia Maria de Aquino Paes; Cibele Rodrigues Bonvicino; Anna Claudia Evangelista Dos Santos; Miguel Angelo Martins Moreira
Journal:  Breast Cancer Res Treat       Date:  2020-10-30       Impact factor: 4.872

3.  Computational analysis of high-risk SNPs in human CHK2 gene responsible for hereditary breast cancer: A functional and structural impact.

Authors:  Nutan V Badgujar; Bhoomi V Tarapara; Franky D Shah
Journal:  PLoS One       Date:  2019-08-09       Impact factor: 3.240

4.  One in three highly selected Greek patients with breast cancer carries a loss-of-function variant in a cancer susceptibility gene.

Authors:  Florentia Fostira; Irene Kostantopoulou; Paraskevi Apostolou; Myrto S Papamentzelopoulou; Christos Papadimitriou; Eleni Faliakou; Christos Christodoulou; Ioannis Boukovinas; Evangelia Razis; Dimitrios Tryfonopoulos; Vasileios Barbounis; Andromache Vagena; Ioannis S Vlachos; Despoina Kalfakakou; George Fountzilas; Drakoulis Yannoukakos
Journal:  J Med Genet       Date:  2019-07-12       Impact factor: 6.318

Review 5.  CHEK2 Germline Variants in Cancer Predisposition: Stalemate Rather than Checkmate.

Authors:  Lenka Stolarova; Petra Kleiblova; Marketa Janatova; Jana Soukupova; Petra Zemankova; Libor Macurek; Zdenek Kleibl
Journal:  Cells       Date:  2020-12-12       Impact factor: 6.600

6.  CHEK2 Pathogenic Variants in Greek Breast Cancer Patients: Evidence for Strong Associations with Estrogen Receptor Positivity, Overuse of Risk-Reducing Procedures and Population Founder Effects.

Authors:  Paraskevi Apostolou; Vasiliki Dellatola; Christos Papadimitriou; Despoina Kalfakakou; Elena Fountzilas; Eleni Faliakou; Georgios Fountzilas; Ourania Romanidou; Irene Konstantopoulou; Florentia Fostira
Journal:  Cancers (Basel)       Date:  2021-04-27       Impact factor: 6.639

7.  RNA Sequencing Provides Evidence for Pathogenicity of a Novel CHEK2 Splice Variant (C.1009-7T>G).

Authors:  Rae Na; Jinyoung Hong; Hyunjung Gu; Woochang Lee; Jae-Lyun Lee; Sail Chun; Won-Ki Min
Journal:  Ann Lab Med       Date:  2022-05-01       Impact factor: 3.464

8.  Germline Testing in a Cohort of Patients at High Risk of Hereditary Cancer Predisposition Syndromes: First Two-Year Results from South Italy.

Authors:  Francesco Paduano; Emma Colao; Fernanda Fabiani; Valentina Rocca; Francesca Dinatolo; Adele Dattola; Lucia D'Antona; Rosario Amato; Francesco Trapasso; Francesco Baudi; Nicola Perrotti; Rodolfo Iuliano
Journal:  Genes (Basel)       Date:  2022-07-21       Impact factor: 4.141

9.  Common clonal origin of chronic myelomonocytic leukemia and B-cell acute lymphoblastic leukemia in a patient with a germline CHEK2 variant.

Authors:  Alexandre Bazinet; John Heath; Anne-Sophie Chong; Estelle R Simo-Cheyou; Samantha Worme; Barbara Rivera Polo; William D Foulkes; Stephen Caplan; Nathalie A Johnson; Alexandre Orthwein; François E Mercier
Journal:  Cold Spring Harb Mol Case Stud       Date:  2021-06-11

Review 10.  Yeast as a Tool to Understand the Significance of Human Disease-Associated Gene Variants.

Authors:  Tiziana Cervelli; Alvaro Galli
Journal:  Genes (Basel)       Date:  2021-08-24       Impact factor: 4.096

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.